305MO SCC244 Plus Osimertinib in Patients with Stage IIIB/IIIC or IV, EGFR TKI Resistant EGFR-mutant NSCLC Harboring MET Amplification
ANNALS OF ONCOLOGY(2022)
Key words
EGFR Mutations
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined